본문 바로가기

Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
피인용
Web of Science 1Scopus 1
FWCI (Scopus)
0.18
JCR IF
JCR 2023 3.8
ISSN
1027-3719

저자

  1. Shin, J. E.제1저자Asan Med Ctr, Div Pulm & Crit Care Med, Seoul, South Korea
  2. 전두수Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan, South Korea
  3. 목정하Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea
  4. Yim, J. -j.Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
  5. Kwon, Y-s.Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea
  6. Jo, K. -w.Univ Ulsan, Coll Med, Div Pulm & Crit Care Med, Seoul, South Korea
  7. Shim, T. S.교신저자Asan Med Ctr, Div Pulm & Crit Care Med, Seoul, South Korea

초록

BACKGROUND: Following the WHO???s announcement in 2018, the use of new drugs was recommended for all patients with multidrug-resistant TB (MDR-TB) in Korea. This study aimed to evaluate adherence to new anti-TB drug regimens and implementation of molecular drug susceptibility testing (mDST) in Korea.METHODS: Nationwide, 560 patients were reported as having MDR-TB in 2021. The implementation of mDST and new anti-TB drug use were analysed. The discrepancy between mDST and phenotypic DST (pDST) results and their implications on the use of new anti-TB drugs were also analysed. The use of novel anti-TB drugs has been approved by the National TB Expert Committee.RESULTS: The non-adherence rate in MDR-TB patients was 14.3%. The mDST implementation rate was 96.1%. Of the 459 patients who underwent both mDST and pDST, the discordance rate for rifampicin (RIF) resistance was 22.6% (n = 104), of which 72.1% (n = 75) were resistant on mDST but susceptible on pDST. The discrepancy in mDST and pDST results related to RIF resistance was found to be the main cause of non-adherence to new drug regimen.CONCLUSION: Comprehensive training on how to interpret conflicting results between mDST and pDST could enhance the utilisation of new drugs in the treatment of MDR/RIF-resistant TB.

키워드

MULTIDRUG-RESISTANT TUBERCULOSISMYCOBACTERIUM-TUBERCULOSISTREATMENT OUTCOMESRIFAMPINBEDAQUILINEDELAMANID

식별자

Scopus EID
2-s2.0-85184344650
WoS UID
001222190700002